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Abstract
Background: Cancer patients often suffer from emotional distress as a result of the oncological process. The purpose of
our study was to determine whether practice of Jacobson’s relaxation technique reduced consumption of psychotropic
and analgesic drugs in a sample of cancer patients.
Methods: This was a multicenter pre–post intervention design. Participants were 272 patients aged over 18 years
attending 10 Spanish public hospitals with oncological pathologies and anxiety symptoms. The intervention
consisted of a protocol of abbreviated progressive muscle relaxation training developed by Bernstein and Borkovec.
This was followed up by telephone calls over a 1-month period. The intervention was performed between November
2014 and October 2015. Sociodemographic variables related to the oncological process, mental health variables, and
intervention characteristics were measured.
Results: A reduction in the consumption of psychotropic and analgesic drugs was observed throughout the follow-up
period. Improvement was observed throughout the 4-week follow-up for all the parameters assessed: anxiety,
relaxation, concentration, and mastery of the relaxation technique.
Conclusions: The practice of abbreviated Jacobson’s relaxation technique can help to decrease the consumption of
psychotropic and analgesic drugs. Patients experienced positive changes in all the evaluated parameters, at least during
the 1-month follow-up. To confirm these findings, additional long-term studies are needed that include control groups.
Trial registration: ISRCTN 81335752, DOI 10.1186/ISRCTN81335752 17.
Date of registration: 22/11/2016 (retrospectively registered).
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Background
It has been estimated that between 20% and 50% of pa-
tients with cancer experience pain [1] and this estimate
increases to up to 90% when the illness is very advanced
[2]. Furthermore, approximately 30% of patients experi-
ence emotional distress during the course of treatment
[3, 4].
The management of oncological pain is particularly
difficult and although different recommendations
exist, there is currently no clear consensus. The World
Health Organization, the American Cancer Society,
and the European Society for Medical Oncology men-
tion in their guidelines on managing cancer pain the
importance of medications (aside from analgesic treat-
ment) such as psychotropic drugs, although they
stipulate that these should be taken only for pain that
may otherwise be unmanageable or difficult to control
[5–7]. Despite following these recommendations, a
high percentage of patients cannot control their pain.
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A literature review by Deandrea et al. [8] reported that
approximately 43.4% are unable to control their pain
and some sources suggest that this figure may be as
high as 80%.
Cancer patients often experience emotional distress,
such as anxiety and depression, and may consume
psychotropic drugs to manage both pain and emo-
tional symptoms [9–11].
Previous studies indicate that the consumption of
psychotropic drugs, especially anxiolytics and antide-
pressants, is high among cancer patients. Syrowatka
et al. [12] reported a consumption of 50.6% of anxio-
lytics in women with breast cancer. Barry et al. [13]
found that 51% of patients with metastasis cancer
took anxiolytics for pain during the active treatment
phase. The consumption of antidepressants has been
reported as between 10% and 64% [12–14]. Thus,
research indicates that a large number of patients
consume three or more psychotropic drugs [13].
It is clear, therefore, that consumption of a combin-
ation of analgesic and psychotropic drugs is common
in cancer patients. Indeed, Kierner et al. [15] reported
that the prevalence of consumption of psychotropic
drugs and analgesics was as high as 75% and 90%, re-
spectively, during the final illness phases. These re-
sults suggest that consumption increases with the
evolution of the illness.
Polypharmacy in oncological patients is therefore a
problem. In addition, although cancer patients may
take a range of drugs, they may not always manage
to control their symptoms.
Oncological patients are often treated with a range of
drugs (e.g., anticancer, antiemetic, psychopharmaceuti-
cal, and analgesic drugs), which increases the risk of
drug interactions and adverse effects [16]. The risks of
polypharmacy also include an increase in episodes of
falls, frailty, hospitalization, postoperative complications,
and even higher mortality [16]. All these problems can
lead to greater disability and lower patient autonomy,
particularly for older patients [17].
This evidence highlights the need for strategies that
can control pain and emotional distress in patients
undergoing complex oncological processes but that help
to decrease polypharmacy as much as possible.
There is evidence that complementary therapies, such
as muscle relaxation, are effective in improving the qual-
ity of life of patients with cancer [18–26]. However,
there is a lack of research on the effect of such therapies
on pain and the consumption of psychotropic drugs and
analgesics in cancer patients.
Therefore, the aim of this study was to determine
whether the practice of Jacobson’s relaxation technique
reduced consumption of psychotropic and analgesic
drugs in a sample of cancer patients.
Methods
Design
This was a multicenter pre–post intervention study. The
study was conducted in accordance with the CONSORT
guidelines.
Participants
The study was conducted between November 1, 2014,
and October 1, 2015, in the oncological units of 10
Spanish public hospitals. Patient recruitment took place
in these units using posters, informative flyers, and
information provided to relevant health professionals
(oncologists, nurses, and psychologists). Cancer pa-
tients exhibiting anxiety, muscular tension, sleeping dif-
ficulties, sadness, or anxiety attacks, and who agreed to
participate, were recruited. The exclusion criteria were
patients exhibiting hallucinations, delirium, or other
psychotic symptoms, because the practice of muscle re-
laxation can lead to potentially unpleasant extracorpor-
eal sensations.
Data collection
The following participant data were collected: 1) socio-
demographic and medical characteristics: medical center,
age, gender, marital status, and educational level; 2)
oncological process: cancer diagnosis, cancer therapy
(chemotherapy, radiotherapy, hormone therapy, bio-
logical therapy, and surgery), any side effects of the can-
cer treatment, cancer pain, and analgesic use; 3) mental
health issues: use of anxiolytics, hypnotics, and antide-
pressants; 4) other variables related to the intervention,
such as symptoms motivating inclusion in the study and
questions such as “Have you practiced the technique at
home?” or “What is the frequency, per week, that you
practice the technique?” Participants were also asked
whether the technique helped them control the anxiety
and pain. Finally, the level of anxiety prior to the session
was recorded, together with the degree of relaxation
achieved, the degree of concentration during the exer-
cises, the command of the technique, and the level of
confidence in its use.
One researcher collected data on the day of the session
and once a week during the 4 weeks follow-up via phone
communication.
In this study, the effect of the intervention on medica-
tion consumption could only be assessed for drugs
issued as emergency prescriptions or refills.
Sample size calculation
The sample size was calculated using EPIDATA version
4.1. As different hospitals were gradually included
throughout the study, we estimated the sample size
based on an infinite population-based sample. With a
95% confidence level, an expected proportion of 20% of
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anxiety disorders in the cancer population, and a
maximum error of estimation of 5%, the estimated
sample size was 246 patients. An expected loss rate
of 5% was assumed; therefore, the final estimated
sample size was 259 patients.
Intervention
A guided session was organized for all participants to
teach them the abbreviated progressive muscle relax-
ation training developed by Bernstein and Borkovec [27].
The sessions were conducted individually or in groups,
according to the needs of each patient. To reduce pos-
sible interexaminer bias and ensure consistency in the
selection criteria, all researchers conducting the inter-
vention had been fully trained on the selection criteria,
the information provided to participants, the data collec-
tion procedures, and the application of the technique.
Written guidance on the relaxation sessions was distrib-
uted to all researchers. The main researcher was present
at the initial treatment intervention at all hospital cen-
ters. A pilot test was performed with the initial 30
patients. Patients were seated during the performance of
the technique, which took place in comfortably furn-
ished rooms with armchairs, cushions, soothing lighting,
and an overall tranquil environment. Each session lasted
for approximately 1 h and consisted of an explanation of
the main characteristics of the abbreviated Jacobson’s re-
laxation technique developed by Bernstein and Borkovec
[27]; a relaxation session; an opportunity for participants
to ask questions; and data collection using a data collec-
tion notebook established for this study.
Upon completion of the session, patients were given
an information sheet about the intervention. This
comprised a brief description of the session, based on
text and images, to help them practice the technique
at home.
Ethical considerations
Ethical approval was granted by the corresponding clinical
research ethical committee of each center involved in the
study [28] (University Hospital of Getafe, 06/26/2014;
Puerta del Hierro-Majadahonda, 07/24/2014; Foundation
Alcorcon, 11/03/2014; Fuenlabrada, 12/03/2014; Bellvitge,
09/10/2014; Salamanca, 07/18/2014; Navarra, 03/27/2015;
Hospital Germans Trias i Pujol, 11/21/2014; and Cantab-
ria 08/01/2014). All data were treated anonymously and
confidentially according to the Spanish Personal Data Pro-
tection Act [29]. The trial was registered with ISRCTN
(trial number 81335752). The clinical trial registration was
postponed because the study was registered with the
Spanish Agency of Medicine and, therefore, inclusion in
the Spanish Registry of Clinical Studies was not required.
Fig. 1 Flowchart of study participants
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In addition, the study sponsor considered the study to be
a behavioral intervention rather than a clinical trial owing
to the lack of drugs, biologics, and devices. All procedures
were conducted according to the Declaration of Helsinki
[30]. All participants provided written informed consent
after having been fully informed about the study aims.
Finally, although adverse effects from the practice of this
technique have not been reported, it is important to
emphasize that these types of techniques are not a substi-
tute for medical treatment.
Data analysis
The SAS v9.3 software (SAS Institute Inc., Cary, NC,
USA) was used for statistical analyses. The level of signifi-
cance for statistical decision-making was set at 0.05. A de-
scriptive univariate analysis was conducted: for qualitative
variables we report percentages and 95% confidence











University Hospital of Getafe,
Madrid.
17 6.39 3.44–9.34
University Hospital of Fuenlabrada,
Madrid.
52 19.55 14.76–24.34
Catalan Institute of Oncology,
University Hospital of Bellvitge,
Barcelona.
35 13.16 9.08–17..24
Catalan Institute of Oncology,
University Hospital “Germans
Trias i Pujol”, Barcelona.
45 16.92 12.39–21.44
Hospital “Sierrallana”, Cantabria. 4 1.50 0.03–2.97
Hospital of Navarra, Navarra. 47 17.67 13.06–22.27
Hospital of Salamanca, Salamanca. 5 1.88 0.24–3.52
University Hospital “Puerta de
Hierro-Majadahonda”, Madrid.
10 3.76 1.46–6.06
AGE (years) Mean [SD] 52.56 [11.33]
Gender
Female 203 76.32 71.18–81.45
Male 63 23.68 18.55–28.82
Marital status
Married 178 66.92 61.24–72.6
Single 39 14.66 10.39–18.93
Divorced 11 4.14 1.73–6.54
Widowed 10 3.76 1.46–6.06
Separated 11 4.14 1.73–6.54
Domestic partnership 17 6.39 3.44–9.34
Educational level
Elementary 131 49.25 43.21–55.28
Secondary 87 32.71 27.04–38.37
University 48 18.05 13.4–22.69
Cancer diagnosis
Lung 31 11.65 7.78–15.52
Digestive 36 13.53 9.4–17.66
Head and neck 5 1.88 0.24–3.52
Gynecological 139 52.26 46.23–58.29
Urinary 7 2.63 0,7–4.56
Hematological malignancies 41 15.41 11.05–19.77
Others 7 2.63 0.7–4.56
Cancer therapy
Chemotherapy 256 96.24 93.94–98.54
Radiotherapy 121 45.49 39.48–51.5




Hormone therapy 52 19.55 14.76–24.34
Biological therapy 50 18.80 14.08–23.51
Surgery to remove cancer 147 55.26 49.26–61.27
Side effects of cancer treatment
No 35 13.16 9.08–17.24
Yes 231 86.84 82.76–90.92
Cancer pain
No 142 53.38 47.36–59.41
Yes 124 46.62 40.59–52.64
Use of analgesics
No – –
Yes 124 100 –
Use of anxiolytics
No 182 68.42 62.81–74.03
Yes 84 31.58 25.97–37.19
Use of antidepressants
No 234 87.97 84.04–91.9
Yes 32 12.03 8.1–15.96
Use of hypnotics
No 208 78.20 73.21–83.18
Yes 58 21.80 16.82–26.79
Symptoms of inclusion in the study
Anxiety 261 98.12 96.48–99.76
Insomnia 37 13.91 9.73–18.09
Sadness 15 5.64 2.85–8.42
Muscle tension 3 1.13 0–2.4
SD Standard deviation, CI Confidence interval
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intervals (CI) for each category; and for quantitative vari-
ables we report means and standard deviations (SD).
To determine changes in the assessed variables
throughout the 4 weeks, we used adjusted models for
each assessment according to the week and the initial
assessment, and incorporated repeated measures of each
subject throughout the entire 4-week period [31]. Logis-
tic regression was used for qualitative variables (“Have
you practiced the technique at home?”, “Do you think
that the technique is helping you to control the anxiety
symptoms?”, “Do you think that the technique is helping
you to control the pain?”), and linear regression was
used for quantitative variables (anxiety, relaxation, con-
centration, and mastery of the technique). We calculated
estimates and 95% CIs of the mean (or percentage) for
each assessment and week, and calculated adjusted con-
trasts using the Tukey correction to analyze differences
in the variables between 2 consecutive weeks.
Results
Initial recruitment comprised 272 patients from the
oncological services of the participating hospitals who
were experiencing anxiety, satisfied all eligibility criteria,
and agreed to participate. Of these, six (2%) were
excluded from the analysis, as they failed to practice the
technique at home (Fig. 1).
Table 1 describes the sociodemographic characteris-
tics, medical characteristics, and effects of the interven-
tion for patients that practiced the technique at home.
The mean age was 52.56 years [SD, 11.33 years], and 76.
32% (95% CI, 71.18–81.45) of the sample were women.
Up to 96.24% (95% CI, 93.94–98.54) were receiving
chemotherapy treatment and 86.84% (95% CI, 82.76–90.
92) reported side effects. In total, 46.62% (95% CI, 40.
59–52.64) reported pain, for which 100% took an anal-
gesic. Regarding psychotropic drugs, 31.58% (95% CI, 25.
97–37.19) took anxiolytics, 12.03% (95% CI, 8.1–15.96)
took antidepressants, and 21.80% (95% CI, 16.82–26.79)
took hypnotics.
Table 2 shows the changes over the 4 weeks in anxiety,
relaxation, concentration, and mastery of the technique,
and the tests of fixed effects in the model (using the type
III sum of squares test). Changes in the assessed param-
eters were influenced by the 4-week follow-up as a co-
variate and by the initial value. The anxiety level prior to
the session was positively influenced by the initial value
(F(1,1014) = 2464.7; p < 0.001) and negatively influenced
by the 4-week follow-up (F(3,1014) = 11.66; p < 0.001). In
the other models, the value of the assessed parameters
was positively influenced by the initial value and by the
4-week follow-up.
Table 3 highlights the differences in estimates for
the parameters evaluated for each of 2 consecutive
weeks. This enabled us to follow the changes in each
parameter using the estimated difference between 2
consecutive weeks. As the table shows, for all the
assessed parameters, there was a statistically signifi-
cant difference between at least one pair of consecu-
tive weeks. The differences between 2 consecutive
weeks were statistically significant for each pair of
consecutive weeks for relaxation, concentration, and
mastery of the technique.
Table 4 shows the consumption reduction for psycho-
tropic and analgesic drugs throughout the 4 weeks of
follow-up. After the intervention, a maximum of 14.71%
(95% CI, 5.55–23.86) patients did not require anxiolytics
after 1 week, and a maximum of 26.47% (95% CI, 15.25–
Table 2 Evolution throughout the 4 weeks for anxiety,
relaxation, concentration and mastery over the technique
variables
Number Mean 95%CI
Level of anxiety prior to the session
Day of the intervention 266 3.99 3.63–4.34
Week 1 254 3.87 3.54–4.20
Week 2 257 3.52 3.25–3.79
Week 3 254 3.35 3.08–3.63
Week 4 254 3.26 2.98–3.54
Level of relaxation achieved
Day of the intervention 266 5.19 4.88–5.49
Week 1 254 3.70 3.52–3.88
Week 2 257 5.46 5.28–5.64
Week 3 254 6.12 5.95–6.28
Week 4 254 6.55 6.38–6.72
Level of concentration during the exercises
Day of the intervention 266 4.11 3.85–4.36
Week 1 254 3.33 3.15–3.50
Week 2 257 4.51 4.32–4.70
Week 3 254 5.17 4.98–5.36
Week 4 254 5.74 5.57–5.92
Mastery over the technique
Day of the intervention 266 3.28 3.06–3.49
Week 1 254 3.83 3.63–4.03
Week 2 257 4.29 4.07–4.51
Week 3 254 4.98 4.78–5.18
Week 4 254 5.48 5.29–5.67
Confidence in its usefulness
Day of the intervention 266 5.95 5.73–6.18
Week 1 254 6.20 5.98–6.42
Week 2 257 6.27 6.06–6.48
Week 3 254 6.59 6.39–6.79
Week 4 254 6.86 6.66–7.05
CI Confidence Interval
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37.69) patients per week required these drugs on fewer
occasions.
Finally, Table 5 describes the effects of the intervention
for patients who practiced the technique at home.
Throughout the 4-week follow-up period, over 95% of
patients had practiced the technique at home, and the
mean frequency of practice per week was 6.19–6.57.
Over 97% of patients each week reported that relaxation
had helped them to control anxiety symptoms. Between
21.01% and 22.69 of patients with pain reported an im-
provement in pain control.
A maximum of 12.5% (95% CI, 4.19–26.80) patients
did not require hypnotics after 1 week and a maximum
of 15% (95% CI, 2.68–27.32) required them on fewer
occasions. Finally, after the intervention, a maximum of
38.5% (95% CI, 0.47–13.21) patients did not require an-
algesics after 1 week and a maximum of 30.77% (95% CI,
17.26–44.27) required them on fewer occasions. Further-
more, a maximum of 17.31% (95% CI, 6.06–28.55) of
patients reported that the analgesics were more effective.
Discussion
The practice of complementary techniques that induce
relaxation can improve the quality of life of patients
[18–26], and this can result in a decrease of the con-
sumption of certain drugs for some patients.
Between 97.24% and 97.24% of patients who practiced
the technique reported an improvement in anxiety. This
led to a reduction in the consumption of anxiolytics in a
maximum of 26.47% of patients after 1 week and a max-
imum of 14.71% of patients after 1 week did not require
anxiolytic medication.
These results support previous findings by Beard et al.
[23], who found statistically significant differences in
pre–post anxiety measurements in groups treated with
Reiki and relaxation compared with a control group. In
addition, Isa et al. [24, 25] investigated the effect of
muscle relaxation on anxiety and stress levels among
patients with prostate cancer and reported significant
differences at 4 and 6 months.
Other complementary therapies have also demon-
strated effectiveness in controlling anxiety. Yoga signifi-
cantly reduced both initial and final anxiety levels
(measured using the State–Trait Anxiety Inventory) after
an 8-week intervention [21]. A study of patients with
breast cancer showed a significant improvement on
Hospital Anxiety and Depression Scale scores after
weekly acupuncture treatment [20]. The effect of muscle
relaxation on the control of anxiety has also been stud-
ied in non-oncological patients, such as pregnant
women [32], patients with dental anxiety [33], pulmon-
ary hypertension patients [34] and schizophrenia
patients [35].
None of these studies investigated the consumption of
psychotropic drugs. Our findings suggest that comple-
mentary therapies could help patients to reduce the con-
sumption of emergency or refill prescription drugs, as
was the case for the patients in our sample.
Despite the fact that patients reported improvements
in pain (21.01%–22.69%), this effect had a moderate im-
pact on analgesic consumption (up to 3.85% of partici-
pants did not require these and up to 30.77% required
them on fewer occasions). Notwithstanding, some
patients reported that the analgesics were more effective
Table 3 Highlights the differences in estimation for the parameters evaluated for each two consecutive weeks
Comparison Estimate of the difference
Time 1 Time 2 Estimate of the difference 95%CI inferior 95%CI superior p value*
Level of anxiety prior to the session Week 1 Week 2 0.32 0.03 0.61 0.023
Week 2 Week 3 0.20 −0.09 0.48 0.296
Week 3 Week 4 0.10 −0.19 0.39 0.817
Level of relaxation achieved Week 1 Week 2 −1.75 −2.06 −1.45 <.001
Week 2 Week 3 −0.66 − 0.97 − 0.36 <.001
Week 3 Week 4 −0.43 − 0.74 − 0.13 0.001
Level of concentration during the exercises Week 1 Week 2 −1.17 − 1.47 −0.88 <.001
Week 2 Week 3 −0.67 −0.97 − 0.38 <.001
Week 3 Week 4 −0.57 −0.87 − 0.28 <.001
Mastery over the technique Week 1 Week 2 −0.45 −0.74 − 0.15 <.001
Week 2 Week 3 −0.70 −1.00 −0.41 <.001
Week 3 Week 4 −0.50 −0.79 − 0.20 <.001
Confidence in its usefulness Week 1 Week 2 −0.06 −0.27 0.15 0.865
Week 2 Week 3 −0.33 −0.54 − 0.12 <.001
Week 3 Week 4 −0.27 −0.48 − 0.06 0.006
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(17.31%). Neither Beard et al. [23] nor Andersen et al.
[19] (who studied muscle relaxation in cancer patients)
investigated pain; however, the literature suggests that
techniques that involve relaxation, such as music therapy
and yoga, can improve pain control [21, 35–41].
Patients experienced positive changes in all the param-
eters studied throughout the 1-month follow-up. As pa-
tients continued to practice the technique, they
experienced an increase in relaxation, concentration,
mastery of the technique, and confidence in its useful-
ness, at least during the first month. Furthermore, anx-
iety levels prior to the relaxation session decreased over
the weeks, suggesting a greater control over anxiety. Our
relaxation protocol only included a 1-month follow-up,
and we found improvements after the first week. Other
similar studies [19, 23–25] have lasted for several weeks
or months. At present, there is a lack of research on the
use of this technique with similar follow-up periods in
cancer patients. Thus, future studies need to assess the
long-term effect of the intervention.
One of the main differences between our intervention
and those used in previous studies is the simplicity of
the training. Patients only required a 1-h session to learn
the technique, which can be performed in a few minutes
Table 4 Use of psychotropic and analgesic drugs after the
intervention
N = 266 Percent 95%CI
ANXIOLYTIC USE 84 31.58 25.81–37.65
Consumption “on demand” 68 80.95 71.96–89.95
Does not require anxiolytics
Week 1 8 11.76 3.37–20.16
Week 2 9 13.23 4.45–22.03
Week 3 10 14.71 5.55–23.86
Week 4 10 14.71 5.55–23.86
Requires anxiolytic on fewer occasions
Week 1 18 26.47 15.25–37.69
Week 2 6 8.82 1.35–16.30
Week 3 6 8.82 1.35–16.30
Week 4 6 8.82 1.35–16.30
HYPNOTIC USE 58 21.80 16.65–26.95
Consumption “on demand” 40 68.97 56.20–81.73
Does not require hypnotics
Week 1 1 2.5 0.06–13.16
Week 2 3 7.5 1.57–20.39
Week 3 4 10 2.79–23.66
Week 4 5 12.5 4.19–26.80
Requires hypnotics on fewer occasions
Week 1 5 12.5 4.19–26.80
Week 2 6 15 2.68–27.32
Week 3 5 12.5 4.19–26.80
Week 4 4 10 2.79–23.66
USE OF ANALGESICS 124 46.62 40.43–52.80
Emergency prescriptions 52 41.94 32.85–51.02
Does not require analgesia
Week 1 2 3.85 0.47–13.21
Week 2 2 3.85 0.47–13.21
Week 3 2 3.85 0.47–13.21
Week 4 2 3.85 0.47–13.21
Requires analgesia on fewer occasions
Week 1 16 30.77 17.26–44.27
Week 2 16 30.77 17.26–44.27
Week 3 16 30.77 17.26–44.27
Week 4 16 30.77 17.26–44.27
Analgesics are more effective
Week 1 9 17.31 6.06–28.55
Week 2 8 15.38 4.62–26.15
Week 3 8 15.38 4.62–26.15
Week 4 8 15.38 4.62–26.15
CI Confidence interval




Have you practiced the technique at home?
Week 1 254 95.49 92.98–97.99
Week 2 257 96.62 94.43–98.8
Week 3 254 95.49 92.98–97.99
Week 4 254 95.49 92.98–97.99
How many times have you practiced the technique per week?
Week 1 Mean [SD] 254 6.57 [4.36]
Week 2 Mean [SD] 257 6.46 [3.62]
Week 3 Mean [SD] 254 6.24 [3.57]
Week 4 Mean [SD] 254 6.19 [3.65]
Do you consider that the technique is helping you to control the
symptoms derived from anxiety?
Week 1 247 97.24 95.22
Week 2 250 97.28 95.28–99.28
Week 3 248 97.64 95.76–99.51
Week 4 248 97.64 95.76–99.51
Do you consider that the technique is helping you to control the pain?
Week 1 27 22.69 15.13–30.25
Week 2 25 21.01 13.66–28.36
Week 3 26 21.85 14.39–29.31
Week 4 26 21.85 14.39–29.31
SD Standard deviation,CI Confidence interval
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in a seated position. Furthermore, although the tech-
nique is more effective if practiced in a silent environ-
ment with dimmed light, it can be performed anywhere.
Therefore, this protocol could be implemented in differ-
ent hospitals, as it does not require complex resources.
Although complementary techniques are increasingly
used in oncology, there are not enough studies to com-
pare our results to; therefore, further studies on this
technique are required.
This study has several strengths, such as the use of a
large sample from different hospitals (i.e., this was a
multicenter study) and the training of staff in the tech-
nique. However, there are potential limitations. The lack
of a control group means that we cannot confirm that
the results derived solely from the intervention. How-
ever, the inclusion of control/placebo groups in studies
of cancer patients is a challenging procedure from an
ethical perspective. In addition, patients were recruited
in hospitals using informative flyers, posters, and direct
information provided by health professionals caring for
the patients. Therefore, we cannot confirm exactly how
many prospective participants received this information.
Finally, we only evaluated short-term effects of the inter-
vention, so are unable to determine the long-term
effects. Nevertheless, as the mortality rate of several can-
cer types included in the current study was high, this
would be challenging data to obtain in future studies.
Conclusions
The practice of abbreviated Jacobson’s relaxation tech-
nique developed by Bernstein and Borkovec [27] helped to
reduce the consumption of psychotropic and analgesic
drugs. Patients experienced positive changes in all the
evaluated parameters, at least during the 1-month follow-
up. To confirm our findings, additional long-term inter-
vention studies are needed that include control groups.
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